Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,341 to 1,360 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recent Developments in PROTAC-Mediated Protein Degradation: From Bench to Clinic. | Chembiochem | 2022 | 34494353 | PubTator, text mining | PubMed |
| A NSD3-targeted PROTAC suppresses NSD3 and cMyc oncogenic nodes in cancer cells. | Cell Chem Biol | 2022 | 34469831 | PubTator, text mining | PubMed |
| Unleashing the power of NK cells in anticancer immunotherapy. | J Mol Med (Berl) | 2022 | 34374809 | PubTator, text mining | PubMed |
| Protein degradation: a novel computational approach to design protein degrader probes for main protease of SARS-CoV-2. | J Biomol Struct Dyn | 2022 | 34328382 | PubTator, text mining | PubMed |
| Understanding MCL1: from cellular function and regulation to pharmacological inhibition. | FEBS J | 2022 | 34310025 | PubTator, text mining | PubMed |
| Cell cycle on the crossroad of tumorigenesis and cancer therapy. | Trends Cell Biol | 2022 | 34304958 | PubTator, text mining | PubMed |
| Targeting autophagy in disease: established and new strategies. | Autophagy | 2022 | 34241570 | PubTator, text mining | PubMed |
| Synthesis and structure-activity relationships of targeted protein degraders for the understudied kinase NEK9. | Curr Res Chem Biol | 2021 | 40837099 | PubTator, text mining | PubMed |
| The evolving role and utility of off-label drug use in multiple myeloma. | Explor Target Antitumor Ther | 2021 | 36046752 | PubTator, text mining | PubMed |
| Proteolysis-targeting chimeras and their implications in breast cancer. | Explor Target Antitumor Ther | 2021 | 36046115 | PubTator, text mining | PubMed |
| The clinical advances of proteolysis targeting chimeras in oncology. | Explor Target Antitumor Ther | 2021 | 36046114 | PubTator, text mining | PubMed |
| Multi-omics tumor profiling technologies to develop precision medicine in multiple myeloma. | Explor Target Antitumor Ther | 2021 | 36046090 | PubTator, text mining | PubMed |
| Targeted therapy of multiple myeloma. | Explor Target Antitumor Ther | 2021 | 36045700 | PubTator, text mining | PubMed |
| MYC inhibitors in multiple myeloma. | Cancer Drug Resist | 2021 | 35582389 | PubTator, text mining | PubMed |
| CDK4/6 inhibitors: a brief overview and prospective research directions. | RSC Adv | 2021 | 35479560 | PubTator, text mining | PubMed |
| Overcoming drug resistance by targeting protein homeostasis in multiple myeloma. | Cancer Drug Resist | 2021 | 35265794 | PubTator, text mining | PubMed |
| Relapsed and refractory primary CNS lymphoma: treatment approaches in routine practice. | Ann Lymphoma | 2021 | 35253010 | PubTator, text mining | PubMed |
| Options to Improve the Action of PROTACs in Cancer: Development of Controlled Delivery Nanoparticles. | Front Cell Dev Biol | 2021 | 35186955 | PubTator, text mining | PubMed |
| Utilization of CRISPR-Mediated Tools for Studying Functional Genomics in Hematological Malignancies: An Overview on the Current Perspectives, Challenges, and Clinical Implications. | Front Genet | 2021 | 35154242 | PubTator, text mining | PubMed |
Case Report and Literature Review: Diagnosis, Tailored Genetic Counseling and Cancer Prevention for a Locally Advanced dMMR/MSI-H/TMB-H Lung Cancer Patient With Concurrent Lynch Syndrome Mediated by a Rare PMS2 Splicing Variant (c.1144+1G>A). | Front Genet | 2021 | 35116055 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=68